HAE at a glance
HAEMONETICS CORP (HAE, SEC CIK 313143) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 18, 2026 and Form 4 insider filings as recently as July 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 28, 2026 (FY2026), HAEMONETICS CORP (HAE) reported revenue of $1.3 billion (down 2.0% from FY2025) and net income of $97.3 million. Diluted EPS was $2.05.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding HAEMONETICS CORP (HAE) shares worth $1.8 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $1.3B
- −2.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 35 funds
- $1.8B · −1 vs prior quarter
- Latest 8-K
- Aug 18, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 27, 2026
Management Discussion & Analysis
- Revenue $339.4M, up 5.6% YoY from $321.4M
- Operating margin 16.9% vs 16.8%; net margin 9.7% vs 10.6%
- Best segment MedSurg, revenue $148.1M, up 6.0%; Blood Management Technologies up 8.6%
- Worst line Apheresis Other, revenue $35.8M, down 2.4% YoY
- Operating cash flow $52.3M vs $17.4M; $50.0M revolving-credit repayment drove financing outflows of $51.5M
Risk Factors
- No material risk-factor changes from March 28, 2026 Form 10-K
- Carried-forward operational, competitive, and market risks remain as disclosed in the 10-K
- Carried-forward regulatory, legal, and compliance risks remain as disclosed in the 10-K
- Carried-forward liquidity, debt, currency, and concentration risks remain as disclosed in the 10-K
AI summary of the HAE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- CSL supply agreement expected to increase utilization of Haemonetics products at CSL centers
- Fiscal 2027 financial impact timing remains uncertain, with updates anticipated later
Item EX-99.1: Item EX-99.1
- Q1 FY27 revenue $339.4M, up 5.6%, with organic growth 5.9% across Apheresis and MedSurg
- Adjusted EPS $1.14, up 3.6%, despite adjusted operating margin declining 70 basis points to 23.4%
Item 2.02: Results of Operations and Financial Condition
- Q1 fiscal 2026 results covered quarter ended June 27, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management commentary
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Martin Madaus elected Haemonetics director effective July 24, 2026
- Expected Audit and Governance and Compliance Committee assignments
Item 5.07: Submission of Matters to a Vote of Security Holders
- 92.53% quorum; all eight director nominees elected for one-year terms ending 2027
- Executive compensation received advisory approval, 39,212,253 for versus 572,620 against
AI summaries of HAE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HAE
Don't miss the next HAE filing
- Alerts as it files. A push when HAE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HAE, by share count.
- Ask anything. An AI agent that reads every HAE filing and answers with sources.
HAE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Pomeroy Claire | A | Jul 24, 2026 | 2,538 | - |
| ABERNATHY ROBERT E | A | Jul 24, 2026 | 2,538 | - |
| KROLL MARK W | A | Jul 24, 2026 | 2,538 | - |
| COYLE MICHAEL J | A | Jul 24, 2026 | 2,538 | - |
| Zane Ellen M | A | Jul 24, 2026 | 2,538 | - |
| Johnson Lloyd Emerson | A | Jul 24, 2026 | 2,538 | - |
| Bryant Diane M | A | Jul 24, 2026 | 2,538 | - |
| Madaus Martin D | A | Jul 24, 2026 | 2,538 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.4B | $1.3B |
| Gross Profit | - | $749.0M | $787.6M |
| Operating Income | - | $221.8M | $156.7M |
| Net Income | - | $167.7M | $97.3M |
| Gross Margin | - | 55.0% | 59.0% |
| Op. Margin | - | 16.3% | 11.7% |
| Net Margin | - | 12.3% | 7.3% |
| Balance Sheet | |||
| Total Assets | $2.2B | $2.5B | $2.4B |
| Equity | - | $820.8M | $796.3M |
| ROE | - | 20.4% | 12.2% |
| Per Share | |||
| EPS | - | $3.31 | $2.05 |
| Cash Flow | |||
| Operating CF | - | $181.7M | $293.2M |
| CapEx | $66.3M | $39.3M | $32.8M |
Source: XBRL data in HAEMONETICS CORP (HAE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HAE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $1.79B |
| Q1 2026 | 36 | $1.31B |
| Q4 2025 | 29 | $1.99B |
| Q3 2025 | 29 | $1.14B |
| Q2 2025 | 29 | $1.57B |
| Q1 2025 | 25 | $872.7M |
| Q4 2024 | 22 | $918.8M |
| Q3 2024 | 19 | $473.4M |
- Citadel Advisors LLC+1.25M (+485%)
- Millennium Management+560.6K (+5730%)
- BlackRock+289.3K (+5%)
- Dimensional Fund Advisors+259.2K (+20%)
- T. Rowe Price Group+216.5K (+52%)
- AQR Capital Management−1.09M (-32%)
- FMR LLC (Fidelity)−987.8K (-77%)
- D.E. Shaw & Co−154.6K (-81%)
- JPMorgan Chase & Co−101.0K (-31%)
- Prudential Financial−68.7K (-89%)
- Mangrove Partners−21.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HAE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 10-K | May 20, 2026 | Mar 28, 2026 | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 8-K | May 1, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| SC 13G | Mar 3, 2026 | - | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
HAE SEC filings: frequently asked questions
Which institutions hold HAE stock?
As of June 30, 2026, the largest HAEMONETICS CORP (HAE) holders among the 13F filers tracked by SignalX were BlackRock ($443.2 million), Vanguard Portfolio Management LLC ($191.0 million), AQR Capital Management ($165.0 million), Vanguard Capital Management LLC ($154.5 million), State Street Corp ($136.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HAE's revenue in fiscal year 2026?
For the fiscal year ended March 28, 2026 (FY2026), HAEMONETICS CORP (HAE) reported revenue of $1.3 billion (down 2.0% from FY2025) and net income of $97.3 million. Diluted EPS was $2.05. The figures come from the XBRL data in the 10-K.
What did HAE report in its latest 8-K?
HAEMONETICS CORP (HAE) filed an 8-K on August 18, 2026 reporting Item 7.01 (Regulation FD Disclosure). CSL supply agreement expected to increase utilization of Haemonetics products at CSL centers.
What are the latest HAE SEC filings?
HAEMONETICS CORP (HAE) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 18, 2026 and a Form 4 insider filing on July 28, 2026.
What is HAE's SEC CIK number?
HAEMONETICS CORP (HAE)'s SEC Central Index Key (CIK) is 313143. EDGAR lists every HAE filing under that number.
Ask anything about HAE
The research agent reads HAE's filings, financials, insider trades and 13F holders, then answers with sources.